AI-extracted from the 10-Q filed 2026-10-22 — Q3 FY2026 (quarter ended September 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Medpace delivered Q3 revenue of $716M (+8.5% YoY) and net income of $137.5M (+23.7% YoY), driven by growth in Oncology, Metabolic, and CNS therapeutic areas.
Biggest Revenue Drivers
Metabolic$209.2M+5.0% YoY
Second largest therapeutic area
Cardiology$61.4M+3.2% YoY
Stable therapeutic area
Biggest Revenue Drivers
Total revenue: $716M+8.5% YoY
Metabolic$209.2M+5.0% YoY
Second largest therapeutic area
Cardiology$61.4M+3.2% YoY
Stable therapeutic area
Largest Expense Items
Reimbursed out-of-pocket expenses$287.3M+3.8% YoY
Fluctuates based on timing of program initiation and closeout
Direct service costs, excluding depreciation and amortization$204.9M+9.9% YoY
Higher personnel costs to support growth in service activities
Selling, general and administrative$51.8M+7.7% YoY
Higher personnel costs to support growth in service activities
Watch Items from the Filing
Three related-party revenue streams (LIB Therapeutics $1.6M, CinRx Pharma $2.3M in Q3 2026) with CEO board involvement; CinRx revenue declined 78% YoY from $10.4M to $2.3M in Q3.
Backlog of $3.17B (+5.6% YoY) with $1.98B–$2.0B expected to convert in next 12 months; backlog subject to cancellations and timing fluctuations.
Advanced billings of $961.9M (+12.6% YoY) provide strong cash collection cushion, but can reverse if project mix shifts.
CEO and related entities control three Cincinnati office buildings leased to Medpace; $90.6M in related-party operating lease ROU assets as of Sept 30, 2026.
Three derivative lawsuits filed in 2026 regarding book-to-bill ratio disclosures; all three voluntarily dismissed without prejudice as of October 20, 2026.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Ewald Stephen PGeneral Counsel & Corp. Secy.Option exercise · May 28, 2026
Gwadry-Sridhar Femida H.DirectorGrant or award · May 15, 2026
Zander Dani S.DirectorGrant or award · May 15, 2026
Congress trading in MEDP
18 transactions in MEDP reported by 6 members of Congress under the STOCK Act, most recent trade May 15, 2026. Reported transactions, not recommendations.
About Medpace Holdings, Inc. (MEDP): stock profile, AI score and financials
Medpace Holdings, Inc. (MEDP) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MEDP at 75.6/100 on a composite quality score built from its SEC filings, placing it at rank #91 of 2,925 stocks — the top 5% of the AI-ranked universe. MEDP scores in the top quartile across balance sheet strength (97.6), institutional flow (79.9), free cash flow (77.9). Shareholder dilution risk is elevated at 47.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Medpace Holdings, Inc. reports quarterly revenue of $716.0M, net income of $137.5M, an operating margin of 23.1%. Top institutional holders of MEDP by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. MEDP trades on the Nasdaq exchange and files with the SEC under CIK 1668397. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MEDP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medpace Holdings, Inc. directly from SEC EDGAR.